Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Saccharomyces boulardii inhibits NF-kappa B-mediated IL-8 gene expression

S. boulardii produces a soluble anti-inflammatory factor which may mediate beneficial effects in intestinal disease, report researchers at in a late-breaking abstract to the American Gastroenterological Association.

News image

fiogf49gjkf04

The probiotic yeast, Saccharomyces boulardii ameliorates intestinal injury and inflammation caused by a variety of bacterial and viral pathogens.

In this study, researchers from the United States hypothesized that S. boulardii acts by modulating the host's intestinal inflammatory response.

Dr Stavros Sougioultzis's team aimed to identify specific mechanisms for the beneficial effects of S. boulardii. They examined the yeast's ability to influence host cell signaling and pro-inflammatory gene expression.

The active component in S. boulardii is a small (≤1 kD), heat stable, water soluble molecule.
American Gastroenterological Association

The team stimulated HT-29 human colonocytes and THP-1 human monocytes with interleukin (IL)-1 beta, tumor necrosis factor (TNF)-alpha, ToxA (Clostridium difficile Toxin A) or lipopolysaccharide (LPS). This was performed in the presence or absence of S. boulardii culture supernatant (SbS).

They measured the production of the pro-inflammatory chemokine IL-8 in the condition media by Enzyme-Linked Immunosorbent Assay.

The researchers also evaluated IL-8 mRNA levels by RT-PCR.

They measured the effect of SbS on I-kappa B alpha degradation using Western blotting, and on NF-kappa B-DNA binding using Electrophoretic Mobility Shift Assay (EMSA).

In addition, NF-kappa B-regulated gene expression was evaluated by transient transfection of THP-1 cells with an NF-kappa B-responsive luciferase reporter gene.

The researchers found that SbS inhibited IL-8 protein production in IL-1 beta stimulated HT-29 cells by 75% TNF alpha stimulated HT-29 cells by 85%, and ToxA stimulated HT-29 cells by 90% (<0.001 for each). It also prevented upregulation of IL-8 mRNA, as determined by RT-PCR.

The team observed a similar inhibitory effect in IL-1 beta or LPS-stimulated THP-1 cells.

Furthermore, SbS also prevented I kappa B alpha degradation, NF-kappa B - DNA binding and NF-kappa B-reporter gene up-regulation following THP-1 cell activation.

The research team also performed purification and characterization studies. These included cesium chloride density gradient ultra-centrifugation, gel filtration, and matrix assisted laser desorption time of flight mass spectroscopic examination. This analysis indicated that the active component in SbS is a small (≤1 kD), heat stable, water soluble molecule.

The team concluded that S. boulardii produced a soluble factor that inhibits NF-kappa B activation and NF-kappa B-mediated IL-8 gene expression in cytokine-, ToxA- or LPS-stimulated intestinal epithelial cells and monocytes.

They think that this anti-inflammatory factor may mediate S. boulardii's beneficial effects in intestinal disease.

AGA
20 May 2003

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us